NCI-2019-01887

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

This medical study is looking at the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of AGEN1181, an investigational drug, either alone (monotherapy) or in combination with AGEN2034. AGEN1181 is an Fc-engineered anti-CTLA-4 monoclonal antibody. CTLA-4 is a protein that helps cancer cells evade the immune system. AGEN1181 is designed to block CTLA-4, which may help the immune system attack and kill cancer cells. AGEN2034 is an anti-PD-1 monoclonal antibody. PD-1 is another protein that helps cancer cells evade the immune system. AGEN2034 is designed to block PD-1, which may also help the immune system attack and kill cancer cells. The study is being conducted in adult participants with advanced solid tumors who have not responded well to standard treatments.

It’s an open-label, multicenter study, meaning participants will know what drugs they’re taking and the study will be conducted at multiple medical centers.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03860272

NCI-2019-01887

Clinical Trial Site: Sinai

To see all available clinical trials click here.